CD70-targeted therapies could restrict drug resistance in lung cancer

February 20, 2023

Roche Stops Lung Cancer Immunotherapy Trial in Newest Disappointment

July 7, 2024

Roche relying on Polivy’s $2B potential to weather biosimilar storm

August 10, 2021

Must Read

FDA Delays Biohaven’s Approval Decision for Rare Disease Drug Troriluzole

May 20, 2025

Pathos AI Secures $365 Million in Series D Funding to Accelerate AI-Powered Cancer Drug Development

May 20, 2025

Life Sciences Voice Top Five Newsletter

May 20, 2025

About Us

Life Sciences Voice is the leading resource for life sciences executives to get crucial insights, explore the latest innovations, and learn about industry trends. Life Sciences Voice provides the community with thought-provoking commentary in multiple formats covering a range of issues from drug discovery to commercial success.

New Data Positions Immutep’s Immunotherapy Combo as First-Line Option for PD-L1-Negative HNSCC

BioMed X Launches XBridge Program to Support U.S. Reacsearchers Amid NIH Funding Cuts

Taiho spends $400 million with a Swiss partner to “turbocharge” three ADCs to the clinic

Élancé Therapeutics Joins the Race to Develop Next-Generation Obesity Therapies

Vertex Presses Pause on CF Study, Reports Major Write-Down

J&J Gene Therapy Treatment For Vision Loss Fails to Meet Primary Endpoints

Pfizer’s PD-1 Inhibitor Shows Mixed Results in Bladder Cancer Trial

Medtronic Highlights Improved Results with Affera PFA Technology

Pathos AI Secures $365 Million in Series D Funding to Accelerate AI-Powered Cancer Drug Development

Eli Lilly Invests $250 Million to Strengthen Ties with Purdue University

Eli Lilly Secures Rights to Alchemab’s Early-Stage ALS Drug in $415M Deal

J&J MedTech presents the first Ottava surgical robot clinical cases

Wisp Launches Weight Care Vertical for Women with Hormonal Imbalances

PicnicHealth Launches New Service Bringing Observational Clinical Trials to the Virtual Realm

Elon Musk Announces Neuralink’s Second Brain-Computer Chip Implantation in a Patient

The now-urgent automation agenda: out-of-control regulatory workloads necessitate AI adoption

Improving life science R&D outcomes with AI

The medical device sector’s surging regulatory burden: how are suppliers coping?

The Future of Gene Therapies: Three Trends

Commercial

Pathos AI Secures $365 Million in Series D Funding to Accelerate AI-Powered Cancer Drug Development

Eli Lilly Invests $250 Million to Strengthen Ties with Purdue University

Eli Lilly Secures Rights to Alchemab’s Early-Stage ALS Drug in $415M Deal

Biolinq Secures $100 Million to Advance Glucose Biosensor and Expand Commercialization Plans

Sanofi Deepens Autoimmune Push with $1.8B AI Biotech Deal

Eli Lilly provides a $1.4 billion gene therapy contract to struggling...

Editor Picks

CD70-targeted therapies could restrict drug resistance in lung cancer

Roche Stops Lung Cancer Immunotherapy Trial in Newest Disappointment

Roche relying on Polivy’s $2B potential to weather biosimilar storm

Must Read

FDA Delays Biohaven’s Approval Decision for Rare Disease Drug Troriluzole

Pathos AI Secures $365 Million in Series D Funding to Accelerate AI-Powered Cancer Drug Development

Life Sciences Voice Top Five Newsletter

Hot Topics

About Us

Follow Us